SCHEDULE 13G: Invus Public Equities Discloses 8.9% Passive Stake in Nanobiotix S.A.

Invus Public Equities, L.P. and its affiliated entities have filed a Schedule 13G, reporting a passive beneficial ownership of 8.9% in Nanobiotix S.A. as of December 31, 2023.

Summary

• Invus Public Equities, L.P., along with Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Raymond Debbane, collectively reported beneficial ownership of 4,232,829 ordinary shares of Nanobiotix S.A. as of the filing date, April 17, 2025.
• This ownership represents 8.9% of Nanobiotix S.A.'s outstanding shares.
• As of December 31, 2023, Invus Public Equities, L.P. directly held 4,260,176 ordinary shares.
• The percentage of ownership is calculated based on 47,426,851 shares outstanding as of December 31, 2024, as reported in Nanobiotix S.A.'s Annual Report on Form 20-F filed on April 2, 2025.
• The filing indicates sole voting and dispositive power over the reported shares by the reporting persons.
• The CUSIP number 63009J107 is assigned to the American Depositary Shares (ADS) of Nanobiotix S.A., which trade on the Nasdaq Global Market under the symbol 'NBTX', with each ADS representing one ordinary share.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment as it does not contain positive or negative operational or financial news.

Future Outlook

This document is a Schedule 13G filing, which reports passive beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing indicates a significant passive investment by Invus Public Equities in Nanobiotix S.A., a biotechnology company. Such disclosures are common for institutional investors accumulating stakes in publicly traded companies, particularly in sectors like biotechnology which often attract specialized funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence or interest in the company.
• Investment Professionals: Offers data points for tracking institutional ownership and potential shifts in the shareholder base.

Key Dates

Keywords

Nanobiotix S.A., Invus Public Equities, Schedule 13G, Beneficial Ownership, NBTX, SEC Filing, Institutional Investor, Biotechnology, Healthcare, Investment